buletin penyelidikan dan pembangunan (r&d)...
TRANSCRIPT
BULETIN PENYELIDIKAN DAN
PEMBANGUNAN (R&D) FARMASI NEGERI
SELANGOR JULAI-DISEMBER 2017
JAWATANKUASA R&D FARMASI SELANGOR 2017
ISI KANDUNGAN
SENARAI AHLI
JAWATANKUASA
1
PENCAPAIAN KAJIAN
R&D FARMASI
SELANGOR
JULAI— DISEMBER
2017
(PEMBENTANGAN DAN
PERSIDANGAN)
2-6
AKTIVITI DAN LATIHAN
JK R&D FARMASI
SELANGOR DAN
AKTIVITI R&D DI PTJ
JAN — JUN 2017
7-9
PROGRAM AKAN
DATANG
10
PENASIHAT
PN. AKMALYATUN KAMAL BT KAMARUDDIN
TIMBALAN PENGARAH
Cawangan A&P Farmasi BPF, JKN Se-
langor
PENGERUSI
PN. NORHALINA BT SULAIMAN
Pegawai Farmasi UF52
PKD Klang
SETIAUSAHA I
PN. SARAH DIYANA BT SHAFIE
Pegawai Farmasi UF48
Hosp Kajang
SETIAUSAHA II
PN HANIATI BT HASAN
Ketua Pen. Pengarah (A&P) UF52
BPF, Jabatan Kesihatan Negeri Selangor
JK KECIL SAINTIFIK
Aswani Yanti bt Baharuddin Peg.Farmasi UF52 Hosp Ampang
Dr. Wardati bt Mazlan Kepli Peg.Farmasi UF52 Hosp Serdang
Chong Pei Feng Peg.Farmasi UF48 Hosp Sg Buloh
Noorul Aimi bt Daud Peg.Farmasi UF48 Hosp Serdang
Josephine a/l Henry Basil Peg.Farmasi UF48 Hosp Shah Alam
Wan Nor Ashikin bt Wan Ibrahim Ketua Pen. Pengarah Kanan UF52 BPFJKNS
Ruwaida Nur bt Zainol Abidin Peg.Farmasi UF48 Hosp Serdang
Kong Su Shan Peg.Farmasi UF52 Hosp Ampang
Nur Kamalah bt Daud@Mahusain Peg.Farmasi UF52 PKD Hulu Langat
Mogana a/p Mathayena Peg.Farmasi UF44 Hosp Selayang
Puteri Juanita bt Zamri Peg.Farmasi UF48 Hosp Selayang
AHLI JAWATANKUASA R&D FARMASI SELANGOR 2017
JK KECIL LATIHAN
Asmahani bt Ramelan Peg.Farmasi UF52 HTAR
Wong Su Li Peg.Farmasi UF44 PKD Klang
Jaya Mania Rao a/l Ramadoo Peg.Farmasi UF44 Hosp Kuala Kubu Bharu
Teh Wen Yan Peg.Farmasi UF44 HTAJ
Silambarasu a/l Karuppiah Peg.Farmasi UF44 PKD Sabak Bernam
Yah Xin Yun Pen.Pengarah Kanan Farmasi UF44 BPFJKNS
Cindy Fow Peg.Farmasi UF44 Hosp Banting
Dinesh a/l Widiadharan Peg.Farmasi UF44 Hosp Sg Buloh
JK KECIL PENERBITAN
Sia Xin Ni Peg.Farmasi UF44 PKD Gombak
Noor Aini bt Zainal Abidin Peg.Farmasi UF44 Hosp Tanjung Karang
Hazwani bt Harith Peg.Farmasi UF44 Hosp Orang Asli Gombak
Sayeeda Zainab bt Hasnor Peg.Farmasi UF44 PKD Kuala Selangor
Nurul Syazwani bt Mohamad Peg.Farmasi UF44 PKD Kuala Langat
Muhamad Fahmi b Jamil Peg.Farmasi UF44 PKD Petaling
Hafizah bt Hassim Peg.Farmasi UF44 PKD Hulu Selangor
Norfaradila bt Mohamed Peg.Farmasi UF44 PKD Sepang
PENCAPAIAN KAJIAN R&D FARMASI SELANGOR
Ignatius L¹., T. J. Sen¹, W. F. Yen¹, Nor Idha Liana¹, Lina Hazwaniz¹, Dr Laila Kamaliah²
Pharmacy Department, Hospital Selayang
Anaesthesiology Department, Selayang Hospital
INTRODUCTION: HAP and VAP are the second most common causes of nosocomial infection in hospital and reported as the
highest mortality rate compared to other hospital acquired infection. Different regions have different rate of antimicrobial
resistance and pathological pattern. This might imply that available guidelines for the initial empirical treatment would not be able
to provide adequate coverage. This study aims to acquire and establish microbiological data of HAP/VAP in ICU settings,
Selayang Hospital.
METHODOLOGY: A retrospective observational study of ICU adult patients (age ≥ 18 years) in Hospital Selayang based on the
review and data extraction of the selected subjects’ electronic medical records system (EMR) from January to December 2015.
RESULTS: Out of 80 isolates, 78 were gram-negative pathogens and 2 were gram-positive pathogens. The results also revealed
total number of pneumonia which was 76. Most of the samples were from VAP. The most common pathogens are A. baumannii,
P. aeruginosa and K. pneumoniae which were associated with 51%, 20% and 11% of pneumonia, respectively. Among empirical
antibiotics started, carbapenems was the most frequent (42%), followed by cephalosporins (20%) and anti-pseudomonal
penicillins (19%). Empirical antibiotic did not provide adequate antimicrobial coverage in 65% of the non-MRO A. baumannii
isolates. In those isolates, 37.5% of the inadequacy was due to empirical use of cephalosporins and aminopenicillins. A.
baumannii were only found in late onset HAP/VA P whereas P. aeruginosa can be found equally in both early onset and late
onset.
CONCLUSIONS: We were able to precisely determine common pathogens and its susceptibility data. Guidelines completed with
local microbiological data provide better coverage compared to treatment based on the latter alone. We suggest the use of dual
therapy in late onset pneumonia without positive culture. Caution should be exercised when starting very broad spectrum
antibiotics as it can do more harm than good when used without careful considerations.
NMRR ID: NMRR-15-2440-25828
A RETROSPECTIVE STUDY ON LOCAL MICROBIOLOGICAL DATA IN INTENSIVE CARE
UNIT SETTING, HOSPITAL SELAYANG
PENCAPAIAN KAJIAN R&D FARMASI SELANGOR
L. S. Yan1, L. F. Y1., Zailin Junaida M. Z1., Nurul Iffah R1., Sreevidya Kumari K.1., Siti Maryam Z1., P. Vinci1, Mohammad Saiful
B1., Ghaneshwari R1., Dr B. B. Cheak1, Dr W. H. Seng1
Selayang Hospital
INTRODUCTION: There is limited evidence regarding the role of monitoring serum aminoglycosides and vancomycin
concentrations in peritoneal dialysis (PD) patients receiving these antibiotics in PD-related peritonitis.
METHODOLOGY: Data were collected from patients receiving PD in PD unit, Hospital Selayang who experienced PD-related
peritonitis between 1st January 2016 and 30th September 2016. We reported on the therapeutic drug monitoring of gentamicin,
amikacin and vancomycin levels from day 2 until completion of IP antibiotic therapy in PD patients.
RESULTS: Previous dosing regimen of IP gentamicin resulted toxic serum levels in 11%, 50%, 75% and 65% of patients on day
2, 4, 6 and 14 respectively. ISPD recommended dosage of IP gentamicin resulted toxic serum levels in 11%, 15%, 12% and 35%
of patients on day 2, 4, 6 and 14 respectively. Current dosing regimen of IP amikacin resulted in levels greater than 8 mg/L for
0%, 43%, 100% and 71% of patients on day 2, 4, 6 and 14 respectively; whereas IP vancomycin resulted in levels greater than 20
mg/L for 31%, 33%, 0% and 22% of patients on day 2, 4, 6 and 21 respectively.
CONCLUSION: This study demonstrated that drug accumulation occurs with repeated dosing of IP aminoglycosides and
vancomycin. Therapeutic drug monitoring and dosage adjustment are essential to minimize the risk of toxicity. This study will be
continued further to ascertain whether current regimen of IP aminoglycosides and vancomycin adopted results in toxic serum
levels and hence nephrotoxicity after prolonged course of therapy.
NMRR ID: NMRR-15-2189-28501
THERAPEUTIC DRUG MONITORING OF INTRAPERITONEAL AMINOGLYCOSIDES
AND VANCOMYCIN IN PERITONEAL DIALYSIS PATIENTS WITH PERITONITIS AND
THEIR EFFECT ON RESIDUAL RENAL FUNCTION
SELANGOR RESEARCH WEEK 2017
PENCAPAIAN KAJIAN R&D FARMASI SELANGOR
A. Alias, K.Y. Lee, A. Palaniappan, S. Ramaniganthan, K.V. Karuppannan
Pharmacy Department, Hospital Tengku Ampuan Rahimah, Klang
INTRODUCTION: Highly active anti-retroviral therapy (HAART) is a combination of multiple antiretroviral drugs from
different antiretroviral classes required to suppress the virus replication, thus increase the immunological response. In
Malaysia, the agents used for first line treatment include combination of nucleoside reverse transcriptase inhibitor (NRTI)
and non-nucleoside reverse transcriptase inhibitor (NNRTI).
OBJECTIVES: The purpose of this study is to evaluate the factors affecting virological & immunological response and the
incidence of virological failure in association to adherence among HAART naïve patient.
METHOD: The retrospective observational case control study was conducted in RVD Clinic of HTAR, Klang. The total of
130 samples was included. All information was collected analyzed statistically using logistic regression and chi-square test.
RESULTS: As a result, it shown that age, adherence, combination of HAART regimen and NNRTI were the factors that
significantly affect the immunological response (P = 0.03, 0.001, 0.02 & <0.001 respectively). However there is no
significant result with virological response. The level of adherence also was significantly highly associated with faster onset
of virological, immunological response (P<0.05). The higher the score, the more adhere to medication, the faster onset of
virological & immunological response and the less likely to develop virological failure (P<0.001). There were some other
factors that we unable to analyze as time constrain.
CONCLUSION: We believe that our study would initiate an expansion to other study in other centre that allowing
comparison to be made.
ID No.: NMRR-15-235-23954
EVALUATON OF FACTORS AFFECTING VIROLOGICAL AND IMMUNOLOGICAL
RESPONSES OF NEVIRAPINE- AND EFAVIRENZ- BASED HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY REGIMENS IN RETROVIRAL DISEASE NAIVE PATIENTS
Best Oral Presenter
PENCAPAIAN KAJIAN R&D FARMASI SELANGOR
2nd Prize Poster Category
DEVELOPMENT OF WARFARIN APP TO IMPROVE TIME IN THERAPEUTIC RANGE AND REDUCE INCIDENCE OF OVER- AND UNDER-WARFARINIZATION
Shahir Anuar S., Tharshini S., Noor Aini Z. A., Raja Azman R. I.
Pharmacy Department, Hospital Tanjong Karang
INTRODUCTION: The Time in Therapeutic Range(TTR) for warfarin in Hospital Tanjong Karang(HTK) was 46.99%, far
below the target set by WHO (>60%). Moreover, the percentage of under-warfarinization, which puts patients at a higher
risk for thromboembolic events such as stroke was 42.26%. Over-warfarinization, a state where patients are at higher risk
for bleeding events, was 20.08%. These findings are primarily attributed to inaccurate warfarin dosage.
OBJECTIVES: a) To increase average TTR; b) To increase percentage of patients with TTR>60%; c)To reduce percentage
of under-warfarinization and over-warfarinization
METHOD: Our study is a retrospective, observational, cohort study using universal sampling of all patients enrolled in INR
Clinic of HTK, 6 months prior to and after intervention. The strategy is to create a smartphone application to aid healthcare
providers in determining accurate dosages for warfarin. ‘Warfarin Dosing HTK’ is a smartphone application currently
accessible to android users only. The application comprises of three sections; a calculator to calculate warfarin dosage
adjustment, a warfarin-food interaction database, and also a warfarin-drug interaction database.
RESULTS: The average TTR showed an increase of 13.19%, up to 60.18% which achieves the target set by WHO.
Percentage of patients with TTR >60% increased by 15.7%. Both under-warfarinization and over-warfarinization were
reduced by 12% and 3.46% respectively.
CONCLUSION: The app has been proven to improve the management of warfarin patients. Incidence of bleeding and
thromboembolic may be reduced. Results may be replicated if app is used elsewhere. At present, it has been downloaded
more than 10 000 by users from more than 100 countries.
PENCAPAIAN KAJIAN R&D FARMASI SELANGOR
PENYERTAAN PERSIDANGAN YANG LAIN;
1. Hosp. Ampang
Role of intravenous glutamine in haematology patients with chemotherapy induced
oral mucositis
2. PKD Sepang
Prospective observational study of iron preparation presciribing pattern of antena-
tal women attedn the mother and child clinic in Sepang
3. Hosp. Selayang
Peritoneal Dialysis-Related Peritonitis Caused by Achromobactor Denitricants.
Case Report and Review of the Literature
Warfarin Anticoagulation & Outcomes in Petiens with Atrial Fibrillation : A Ret-
rospective Study in Different Types of Ministry Health Treatment Protocol
SELANGOR RESEARCH WEEK 2017 14-16 OGOS 2017
HOSPITAL SELAYANG
17th ASIAN CONFERENCE ON CLINICAL PHARMACY (ACCP) 27-31 JULAI 2017
YOGYAKARTA, INDONESIA
1. Hosp. Tengku Ampuan Rahimah (HTAR)
Evaluaton of Virological and Immunological responses of Nevi-
rapine- and Efavirenz- Based Highly Active Antiretroviral Therapy
Regimens in Retroviral Disease Naive Patients
Evaluation on Effect of Hemodialysis in Vancomycin Level
among End Stage Renal Failure Patients
2. Hosp. Sg. Buloh
A Retrospective Review; Oral Indomethacin vs Oral Paracetamol
for PDA in Neonates
A Review of Guidelines and Evidence Basedbin Managing Sus-
pected Early Onset Neonatal Sepsis
AKTIVITI JK R&D FARMASI SELANGOR JUL—DEC 2017
Mesyuarat JK R&D Bil 2/2017
19 JULAI 2017
03 OGOS 2017
Sesi Pembentangan Kertas Cadangan Penyelidikan Sesi 02/2017 - Tarikh: 3 Ogos 2017 - Para Juri: Pn Asmahani Ramelan, Pn Lee Jian Lynn,
Cik Nor Mazni Bt Mohamad Tamyes, Pn Aliza Alias, Cik Geetha Ng Poh Lee, Pn Adilah Mohd Fazli, Pn SIti Mahanim
03 OGOS 2017
Mesyuarat R&D Jabatan Farmasi, HTAR Klang Agenda:
1) Taklimat 'Introduction to Clinical Research' oleh Pn Lee Jian Lynn
2) Sesi perbincangan Principle Investigator ber-sama penyelidik baru
Penceramah: Pn Lee Jian Lynn
06 DISEMBER
Sesi Pembentangan Kertas Cadangan Penyelidikan Sesi 03/2017 - Tarikh: 6 Disember 2017 - Para Juri: Pn Lee Jian Lynn, Pn Aliza Alias, Pn Siti
Mahanim, Pn Tan Shirlyn
14 DISEMBER
Mesyuarat JK Kecil Penerbitan, JK R&D BIL 2/2017
12-14 SEPTEMBER
Bengkel R&D Farmasi JKNS 2017 - Tempat: PPAS Shah Alam - Penceramah: Assoc Prof Dr Moy
Foong Ming, Faculty of Medicine, UM
AKTIVITI DAN LATIHAN JK R&D FARMASI SELANGOR JUL—DEC 2017
Lokasi ;
Perbadanan Perpustakaan Awam Selangor
Tarikh ;
12-14 September 2017
Penceramah Jemputan ;
Assoc Prof Dr Moy Foong Ming,
Fakulti of Medicine, UM
Objektif;
1. Mendedahkan dan meningkatkan
kemahiran dalam membuat
pembentangan projek penyelidikan
& pembangunan
2. Memantau perkembangan dan
kualiti kajian-kajian saintifik yang
dijalankan dan dijalankan di
peringkat PTJ
3. Menyediakan platform bagi
pembentangan kajian-kajian yang
sedang dijalankan dan yang telah
selesai supaya boleh dibuat
BENGKEL R&D FARMASI JKNS 2017
AKTIVITI DAN LATIHAN JK R&D FARMASI SELANGOR JUL—DEC 2017
Hospital Kajang
Aktiviti R&D : Bengkel Penulisan Manuskrip dan Publication
- Tarikh:30-31/10/2017
- Penceramah: En. Chan Huan Keat, Pegawai Farmasi U48, Pusat
Penyelidikan Klinikal (CRC) Hospital Sultanah Bahiyah
Hospital Selayang
Aktiviti R&D : Basic Study Design Workshop
- Tarikh: 13/2/2017
- Penceramah: Puteri Juanita, Nurah Zainal Abidin, Lee Chee Ming
Aktiviti R&D : Research Proposal Presentation Day
- Tarikh: 21/3/2017
- Penceramah: Nurakmal Baharum (CRC) ,Nadiah Sa’at (CRC),
Dr Neoh Chin Fen
Aktiviti R&D : Statistical Analysis Clinic Day (CRC) Session 1
- Tarikh: 30/5/2017
- Penceramah: Nadiah Sa’at (CRC), Tassha Hilda Adnan (CRC)
Aktiviti R&D : Statistical Analysis Clinic Day (CRC) Session 2
- Tarikh: 4/7/2017
- Penceramah: Nadiah Sa’at (CRC), Tassha Hilda Adnan (CRC)
Aktiviti R&D : Annual Presentation Day
- Tarikh: 18/11/2017
Hospital Sungai Buloh
Aktiviti R&D : Meeting for Research Updates with CRC HSgB
- Tarikh: 13/10/2017
- Penceramah: Nicholas Hing Yee Liang (CRC HSgB)
Hospital Tengku Ampuan Rahimah (HTAR)
Aktiviti R&D : Sesi Pembentangan Kertas Cadangan Penyelidikan
02/2017
- Tarikh:3/8/2017
Aktiviti R&D :Mesyuarat Penyelidikan & Pembentangan Jabatan Far-
masi, HTAR
- Tarikh: 3/8/2017
- Penceramah: Lee Jian Lynn
Aktiviti R&D : Sesi Pembentangan Kertas Cadangan Penyelidikan
03/2017
PROGRAM AKAN DATANG
Tarikh: 4 April 2017 & 7 Ogos 2017
Tempat : Perbadanan Perpustakaan Awam Selangor,
Seksyen 13 Shah Alam
Klinik Mentor - Mentee 2018
Tarikh : 27 - 28 Jun 2018
Tempat: Concorde Hotel, Shah Alam
International Conference on Pharmacy Practice 2018
Tarikh : 14 Mei 2018
Tempat : Wisma MBSA, Shah Alam
Bengkel Research & Oral Presentation 2018
Tarikh : 19 - 21 September 2018
Tempat: Wisma MBSA, Shah Alam
Mini Conference R&D 2018
Tarikh : 9 - 11 Julai 2018
Tempat: Royale Chulan Hotel, Seremban
National Pharmacy R&D Conference 2018